Campaign Story

GeneVerse Analytics was founded to revolutionize preventive healthcare through genomic intelligence. In a world where diseases are treated only after symptoms appear, GeneVerse uses AI-driven genome sequencing to identify health risks years before they surface—enabling people to live longer, healthier lives.

The company developed a proprietary AI engine that analyzes a person’s DNA, lifestyle, and environmental exposure to predict the likelihood of developing chronic conditions such as diabetes, heart disease, or cancer. The system also suggests personalized diets, supplements, and medications, turning genetic data into actionable health insights.

In collaboration with two diagnostic labs in Pune and Hyderabad, GeneVerse has already analyzed over 1,500 genomes with 92% accuracy in disease prediction. Doctors and patients praised the system’s simplicity and affordability compared to global alternatives like 23andMe.

But despite its impact, GeneVerse is running out of oxygen. Genome sequencing is expensive, licensing bioinformatics tools costs millions, and without funding, data storage and compliance systems can’t be maintained. The founders have exhausted their personal savings to keep operations running, and partnerships are on hold due to cash flow issues.

With India’s growing focus on personalized medicine and genomic research, GeneVerse could place the country at the frontier of biotech innovation. But without immediate support, it risks becoming another lost breakthrough buried in financial strain.